STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

IMPACT
SENTIMENT
BMY : NYSE
Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial
clinical trial
IMPACT
SENTIMENT
BMY : NYSE
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma¹
fda approval
IMPACT
SENTIMENT
BMY : NYSE
Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023
IMPACT
SENTIMENT
BMY : NYSE
Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis
IMPACT
SENTIMENT
BMY : NYSE
Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares’ Technology Adoption Partnership Program
partnership
IMPACT
SENTIMENT
BMY : NYSE
Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
IMPACT
SENTIMENT
BMY : NYSE MRTX : Nasdaq
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
acquisition
IMPACT
SENTIMENT
BMY : NYSE
Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials
clinical trial
IMPACT
SENTIMENT
BMY : NYSE
Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023
conferences earnings
IMPACT
SENTIMENT
BMY : NYSE
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#119 Ranked by Market Cap
#4058 Ranked by Stock Gains
#655 Ranked by Dividends

BMY Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About BMY

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.